Literature DB >> 17037267

Multiple comparisons and multiple contrasts in randomized dose-response trials--confidence interval oriented approaches.

Ludwig A Hothorn1.   

Abstract

According to the ICH E9 recommendation, the evaluation of randomized dose-finding trials focuses on the graphical presentation of different kinds of simultaneous confidence intervals: i) superiority of at least one dose vs. placebo with and without the assumption of order restriction, ii) noninferiority of at least one dose vs. active control, iii) identification of the minimum effective dose, iv) identification of the peak dose, v) identification of the maximum safe dose for a safety endpoint, and vi) estimation of simultaneous confidence intervals for "many-to-one-by-condition interaction contrasts." Moreover, global tests for a monotone trend or a trend with a possible downturn effect are discussed. The basic approach involved obtaining multiple contrasts for different problem-related contrast definitions. For all approaches, definitions of relevance margins for superiority or noninferiority are needed. Because consensus on margins only exists for selected therapeutic areas and the definition of absolute thresholds may be difficult, simultaneous confidence intervals for ratio to placebo were also used. All approaches are demonstrated in an example-based manner using the R-packages multcomp (difference), for hypotheses based on difference, and mratios (ratio), for hypotheses based on ratios.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17037267     DOI: 10.1080/10543400600860576

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

1.  Adaptive dose finding based on t-statistic for dose-response trials.

Authors:  Anastasia Ivanova; James A Bolognese; Inna Perevozskaya
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

2.  Change point detection for clustered expression data.

Authors:  Miriam Sieg; Lina Katrin Sciesielski; Karin Michaela Kirschner; Jochen Kruppa
Journal:  BMC Genomics       Date:  2022-07-06       Impact factor: 4.547

3.  Trend tests for the evaluation of exposure-response relationships in epidemiological exposure studies.

Authors:  Ludwig A Hothorn; Michael Vaeth; Torsten Hothorn
Journal:  Epidemiol Perspect Innov       Date:  2009-03-06

4.  A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.

Authors:  Gwendlyn Kollmorgen; Klara Palme; Annette Seidl; Stefan Scheiblich; Fabian Birzele; Sabine Wilson; Christian Clemens; Edgar Voss; Martin Kaufmann; Klaus Hirzel; Natascha Rieder; Ben-Fillippo Krippendorff; Frank Herting; Gerhard Niederfellner
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

5.  Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Authors:  Frieder Bauss; Martin Lechmann; Ben-Fillippo Krippendorff; Roland Staack; Frank Herting; Matthias Festag; Sabine Imhof-Jung; Friederike Hesse; Marc Pompiati; Gwendlyn Kollmorgen; Rita da Silva Mateus Seidl; Birgit Bossenmaier; Wilma Lau; Christian Schantz; Jan O Stracke; Ulrich Brinkmann; Masanori Onda; Ira Pastan; Klaus Bosslet; Gerhard Niederfellner
Journal:  Mol Oncol       Date:  2016-07-14       Impact factor: 7.449

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.